EUCTR2006-000341-19-DE进行中（未招募）不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 1,870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •-Men greater than or equal to 18 years of age with histologically-confirmed prostate cancer.
- •-Current or prior radiographic (ie, x-ray, computer tomography [CT], or magnetic resonance imaging [MRI]) evidence of at least 1 bone metastasis.
- •-Documented failure of at least one hormonal therapy as evidenced by a rising PSA (ie, 3 consecutive determinations, taken at least 2 weeks apart from one another. The third measurement must be greater than or equal to 0.4 ng/mL and taken within 8 weeks prior to randomization).
- •-Serum testosterone level of < 50 ng/dL due to either surgical or chemical castration
- •-Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- •-Adequate organ function as defined by the following criteria:
- •1. serum aspartate aminotransferase (AST) less than or equal to 5 x institutional upper limit of normal (ULN)
- •2. serum alanine aminotransferase (ALT) less than or equal to 5 x ULN
- •3. serum total bilirubin less than or equal to 2 x ULN
- •4. creatinine clearance (Cockcroft-Gault) greater than or equal to 30 mL/min
- •5. albumin-adjusted serum calcium greater than or equal to 2.0 mmol/L (8.0 mg/dL) and less than or equal to 2.9 mmol/L (11.5 mg/dL)
- •-Before any study-specific procedure is performed, the appropriate written informed consent must be obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Current or prior IV bisphosphonate administration for any reason
- •-Current or prior oral bisphosphonate administration for the treatment of bone metastases
- •-Planned radiation therapy or surgery to bone
- •-Prior administration of denosumab
- •-Known brain metastasis
- •-Life expectancy less than 6 months
- •-Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
- •-Active dental or jaw condition that requires oral surgery
- •-Non-healed dental/oral surgery
- •-Planned invasive dental procedure(s) for the course of the study
- •-Evidence of any of the following conditions per subject self report or medical chart review:
- •1. Known history of second malignancy within the past 3 years, except for basal cell carcinoma
- •2. Known infection with human immunodeficiency virus
- •3. Active infection with hepatitis B or hepatitis C virus
- •-Any disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
- •-Thirty days or less since receiving an investigational product or device (ie, does not have marketing authorization) in another clinical trial
- •-Subject with reproductive potential who will not agree to use effective contraception (as defined by the investigator or designee)
- •-Known sensitivity to any of the products to be administered during dosing (eg, zoledronic acid, mammalian derived products, calcium or vitamin D)
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer.Treatment of bone metastases in men with hormone- refractory prostate cancer.EUCTR2006-000341-19-LVAmgen Inc1,700
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaTreatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myelomaMedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-000848-65-CZAmgen Inc1,690
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaTreatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myelomaMedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-000848-65-DEAmgen Inc1,690
进行中（未招募）
1 期
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple MyelomaMultiple MyelomaEUCTR2010-020454-34-SKAmgen Inc1,700
进行中（未招募）
不适用
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer SubjectsMedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2006-000339-93-DKAmgen Inc2,049